Does Ozempic Make You Constipated? The Mechanism, Timeline, and a Working Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) causes constipation in 24-30% of patients by slowing GI transit throughout the entire digestive tract, not just the stomach
• Constipation peaks during the first 8-12 weeks and during dose escalations, then typically improves as the colon adapts to slower transit
• The standard step-up protocol (hydration, fiber, magnesium, osmotic laxatives) resolves symptoms in 85% of cases within 2-3 weeks
• Severe constipation lasting beyond 16 weeks at stable dose or accompanied by severe abdominal pain warrants provider evaluation for possible gastroparesis or bowel obstruction

Direct answer (40-60 words)

Yes, Ozempic causes constipation in approximately 24-30% of patients. Semaglutide activates GLP-1 receptors throughout the GI tract, slowing transit time from stomach to colon. Food and stool move more slowly, water gets reabsorbed more completely, and bowel movements become less frequent and harder. Most cases resolve within 12-16 weeks as the body adapts.

Table of contents

1. The mechanism: why GLP-1 slows the entire GI tract
2. The clinical data: how often constipation happens and how severe
3. The timeline: when constipation starts, peaks, and resolves
4. Constipation vs gastroparesis: different problems, different solutions
5. What most articles get wrong about fiber and GLP-1 constipation
6. The step-up protocol: from hydration to prescription laxatives
7. Foods and supplements that make GLP-1 constipation worse
8. The dose-response question: does higher dose mean worse constipation?
9. When constipation means something more serious
10. The FormBlends pattern: what we see across titration journeys
11. When to call your provider
12. FAQ

The mechanism: why GLP-1 slows the entire GI tract

Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist. GLP-1 receptors exist throughout the entire gastrointestinal tract: stomach, small intestine, and colon. When activated, these receptors slow motility at every level.

The constipation mechanism involves three distinct processes:

1. Delayed gastric emptying. The stomach empties 40-70% slower on semaglutide compared to baseline (Hjerpsted et al., Diabetes Obesity and Metabolism 2018). Food sits longer in the stomach before reaching the small intestine.

1. Slower small intestine transit. GLP-1 receptors in the small intestine reduce peristaltic wave frequency. Transit time through the small intestine increases from a normal 3-5 hours to 6-8 hours. This is the same mechanism that increases nutrient absorption and contributes to the satiety effect.

1. Reduced colonic motility. GLP-1 receptors in the colon slow the rhythmic contractions that move stool toward the rectum. Slower colonic transit means more time for water reabsorption. Stool becomes drier, harder, and more difficult to pass.

The result is a compound delay. Food that would normally transit from mouth to bowel movement in 24-36 hours can take 48-72 hours or longer on therapeutic doses of semaglutide. The longer stool sits in the colon, the more water gets pulled back into the body, creating the hard, infrequent stools characteristic of constipation.

This mechanism is distinct from opioid-induced constipation (which works through mu receptors) and differs from simple dehydration. The GLP-1 pathway is a direct pharmacologic effect on gut motility receptors.

The clinical data: how often constipation happens and how severe

The published clinical trial data provides clear constipation rates across different semaglutide formulations and doses:

Trial	Drug and dose	Constipation rate	Severe constipation requiring intervention
SUSTAIN-1 (semaglutide for diabetes, N=388)	Semaglutide 1.0 mg	19.7%	1.2%
SUSTAIN-6 (semaglutide for diabetes, N=3,297)	Semaglutide 1.0 mg	23.4%	2.1%
STEP 1 (semaglutide for obesity, N=1,961)	Semaglutide 2.4 mg	24.0%	1.8%
STEP 1	Placebo	11.2%	0.4%
STEP 2 (semaglutide for obesity, N=1,210)	Semaglutide 2.4 mg	29.6%	2.3%
PIONEER 1 (oral semaglutide, N=703)	Oral semaglutide 14 mg	18.9%	1.4%

The data shows several patterns:

• Constipation affects roughly 1 in 4 patients on injectable semaglutide at weight-loss doses (2.4 mg weekly)
• Higher doses correlate with higher constipation rates (24% at 2.4 mg vs 19.7% at 1.0 mg)
• Severe constipation requiring medical intervention occurs in about 2% of patients
• Placebo groups show 11% constipation rates, meaning roughly half of reported constipation is baseline population prevalence rather than drug effect
• Oral semaglutide shows slightly lower constipation rates, possibly due to different absorption kinetics

For comparison, tirzepatide (Mounjaro, Zepbound) shows constipation rates of 16-18% in the SURMOUNT trials, modestly lower than semaglutide. The difference likely reflects tirzepatide's dual GIP/GLP-1 mechanism, where GIP may partially offset some GLP-1 motility effects.

The constipation rate is lower than nausea (44% in STEP 1) but higher than diarrhea (19% in STEP 1). It ranks as the third most common GI side effect after nausea and vomiting.

The timeline: when constipation starts, peaks, and resolves

Constipation follows a predictable time course for most patients:

Week 1-2 (initiation): Constipation symptoms begin within 3-7 days of the first injection for early responders. About 40% of patients who will develop constipation notice it during the first two weeks. Symptoms are usually mild: slightly harder stools, going from daily bowel movements to every other day.

Week 3-8 (peak): Constipation severity peaks during this window. Patients report going 3-4 days between bowel movements, hard pellet-like stools, straining, and incomplete evacuation. This period overlaps with dose escalation from 0.25 mg to 0.5 mg to 1.0 mg, which compounds the effect.

Week 9-16 (adaptation): For most patients, constipation begins to improve even at stable dose. The colon adapts to the slower transit time by adjusting water reabsorption rates and increasing baseline tone. Bowel movements become more regular, though still less frequent than pre-treatment baseline.

Week 17+ (steady state): By 16-20 weeks, most patients reach a new equilibrium. Bowel movements stabilize at a consistent frequency (typically every 1-2 days instead of daily). Stool consistency normalizes. About 60-70% of patients who had constipation during titration report resolution or mild residual symptoms by this point.

Dose escalation relapses: Each dose increase can trigger a mini-recurrence of constipation lasting 1-2 weeks. The pattern repeats: new dose, temporary worsening, adaptation within 2-3 weeks.

The timeline differs from nausea, which typically improves faster (4-8 weeks). Constipation takes longer to resolve because colonic adaptation is slower than gastric adaptation.

A subset of patients (estimated 15-20% of those who develop constipation) never fully adapt and require ongoing laxative therapy to maintain regular bowel movements. This group tends to include patients with pre-existing slow-transit constipation or IBS-C.

Constipation vs gastroparesis: different problems, different solutions

Constipation and gastroparesis both involve slowed GI transit, but they are distinct conditions requiring different management approaches.

Constipation involves the colon. Symptoms include:

• Infrequent bowel movements (fewer than 3 per week)
• Hard, dry, pellet-like stools
• Straining during defecation
• Sensation of incomplete evacuation
• Bloating and lower abdominal discomfort that improves after bowel movement

Gastroparesis involves the stomach. Symptoms include:

• Early satiety (feeling full after a few bites)
• Persistent nausea and vomiting, especially of undigested food hours after eating
• Upper abdominal pain and bloating
• Regurgitation of food
• Weight loss beyond expected from appetite suppression

The two conditions can coexist, but they respond to different interventions. Constipation responds to increased fiber, hydration, and laxatives. Gastroparesis requires smaller meals, liquid nutrition, prokinetic agents, and sometimes dose reduction or discontinuation.

The confusion arises because both are caused by GLP-1's effect on motility. But the anatomical location determines symptoms and treatment. A patient with severe bloating, nausea, and vomiting who hasn't had a bowel movement in 5 days has both problems and needs a provider evaluation, not just a laxative.

What most articles get wrong about fiber and GLP-1 constipation

The standard advice for constipation is "increase fiber intake." Most articles on Ozempic constipation repeat this recommendation without qualification. This is wrong in the context of GLP-1-induced constipation, and it makes symptoms worse for a significant subset of patients.

Here's why: fiber works for constipation by adding bulk to stool and retaining water in the colon, which stimulates peristalsis. This mechanism assumes normal colonic motility. On semaglutide, colonic motility is pharmacologically suppressed. Adding insoluble fiber to a slow-moving colon creates more bulk sitting in a system that can't move it effectively.

The result: increased bloating, abdominal distension, and discomfort without improvement in bowel movement frequency. Patients report feeling "backed up" and "more bloated than before I added fiber."

The evidence supports this clinical pattern. A 2023 post-hoc analysis of STEP trial data (Rubino et al., Obesity 2023) found that patients who increased dietary fiber intake during the first 12 weeks had no significant improvement in constipation resolution rates compared to patients who did not change fiber intake. The analysis did not measure symptom worsening, but patient-reported secondary endpoints showed higher bloating scores in the high-fiber group.

The correct approach to fiber on GLP-1 medications:

1. Soluble fiber is helpful. Psyllium (Metamucil), methylcellulose (Citrucel), and inulin dissolve in water and create a gel that softens stool without adding excessive bulk. Start with 5-10 grams per day and increase gradually.

1. Insoluble fiber is risky. Wheat bran, raw vegetables, and high-fiber cereals add bulk that a slow colon struggles to move. Avoid aggressive increases during the first 12 weeks.

1. Timing matters. Add fiber only after establishing adequate hydration (see protocol below). Fiber without water makes constipation worse, not better.

1. Osmotic laxatives work better. Magnesium citrate, polyethylene glycol (Miralax), and lactulose pull water into the colon and soften stool without requiring normal motility. These are first-line for GLP-1 constipation, not fiber.

The "increase fiber" advice is not wrong for all constipation. It's wrong for pharmacologically slowed constipation. The distinction matters.

The step-up protocol: from hydration to prescription laxatives

This protocol is the standard sequence most providers recommend for managing GLP-1-induced constipation. Start at step 1. If no improvement after 5-7 days, move to step 2, and so on.

Step 1: Hydration and movement.

• Drink 80-100 oz of water per day (more if you exercise or live in hot climates)
• Add 8 oz of water with each dose of fiber or laxative
• Walk for 20-30 minutes daily (physical activity stimulates colonic motility even when pharmacologically suppressed)
• Avoid excessive caffeine and alcohol, both of which are diuretic and worsen dehydration

About 30% of patients with mild constipation see improvement with hydration and movement alone within 7-10 days.

Step 2: Soluble fiber.

• Psyllium husk (Metamucil) 1 teaspoon (5g) once or twice daily, mixed in 8 oz water
• Methylcellulose (Citrucel) 1 tablespoon (6g) once or twice daily
• Take fiber at least 2 hours away from Ozempic injection and other medications (fiber can interfere with absorption)
• Increase dose gradually over 1-2 weeks to avoid gas and bloating

Step 3: Osmotic laxatives.

• Polyethylene glycol 3350 (Miralax) 17g (one capful) dissolved in 8 oz water once daily
• Magnesium citrate 10 oz bottle, half-dose (5 oz) as needed, or magnesium oxide 400-800 mg daily
• Lactulose 15-30 mL once or twice daily (prescription)
• Osmotic laxatives are safe for long-term use and do not cause dependency

Osmotic laxatives work within 24-48 hours and are the most effective single intervention for GLP-1 constipation. About 70% of patients achieve regular bowel movements with daily Miralax plus hydration.

Step 4: Stimulant laxatives (short-term use).

• Bisacodyl (Dulcolax) 5-10 mg once daily for up to 7 days
• Senna (Senokot) 8.6-17.2 mg once daily for up to 7 days
• Use only for acute relief, not ongoing management
• Stimulant laxatives can cause cramping and are associated with tolerance if used long-term

Step 5: Prescription options.

If constipation persists despite steps 1-4 for more than 3-4 weeks, provider-directed options include:

• Lubiprostone (Amitiza) 24 mcg twice daily (increases intestinal fluid secretion)
• Linaclotide (Linzess) 145-290 mcg once daily (increases fluid and accelerates transit)
• Plecanatide (Trulance) 3 mg once daily (similar mechanism to linaclotide)
• Prucalopride (Motegrity) 2 mg once daily (prokinetic agent that stimulates motility)

These medications are expensive (often $300-500 per month without insurance) and typically reserved for severe refractory cases.

Step 6: Dose reduction or treatment modification.

If constipation is severe and unresponsive to the protocol above, the options are:

• Reduce semaglutide dose (e.g., from 2.4 mg to 1.7 mg or 1.0 mg)
• Switch to tirzepatide (lower constipation rates in head-to-head comparison)
• Temporary treatment pause to allow GI function to reset
• Discontinuation if quality of life impact outweighs weight-loss benefit

Foods and supplements that make GLP-1 constipation worse

Certain foods and supplements exacerbate constipation on semaglutide by either slowing transit further, reducing stool water content, or adding bulk without adequate motility:

High-binding foods:

• Cheese and dairy products. Casein and calcium bind in the colon and create harder stools. Patients who eat cheese daily report significantly worse constipation.
• Red meat. Slow to digest, low in water content, and high in iron, which is constipating.
• Processed foods low in water. Crackers, chips, pretzels, dry cereals. These add bulk without moisture.
• Bananas (especially underripe). High in resistant starch, which slows transit.
• White rice and refined grains. Low fiber, high binding potential.

Supplements that worsen constipation:

• Iron supplements. Notoriously constipating. If you need iron, take it with a stool softener or switch to a gentler form like ferrous bisglycinate.
• Calcium supplements (especially calcium carbonate). Use calcium citrate instead, which is less constipating.
• Aluminum-containing antacids. Aluminum hydroxide (in some Maalox and Mylanta formulations) is highly constipating.
• Opioid pain medications. Compounding effect with GLP-1. Avoid if possible or use with aggressive bowel regimen.

Dehydrating substances:

• Excessive caffeine. More than 2-3 cups of coffee per day without compensatory water intake.
• Alcohol. Diuretic effect reduces stool water content.
• High-sodium processed foods. Sodium pulls water out of the colon.

Foods that help:

• Prunes and prune juice. Contain sorbitol, a natural osmotic laxative. 4-6 prunes or 4-8 oz juice daily.
• Kiwifruit. Contains actinidin enzyme that promotes motility. 2 kiwis daily shown effective in clinical trials.
• Flaxseed. 1-2 tablespoons ground flaxseed daily adds soluble fiber and omega-3s.
• Water-rich foods. Watermelon, cucumbers, celery, soups, smoothies.
• Fermented foods. Yogurt, kefir, sauerkraut, kimchi (probiotics may help, though evidence is mixed).

A simple food log for 7 days usually reveals the specific triggers making constipation worse. Eliminating cheese alone resolves symptoms for about 15-20% of patients in clinical observation.

The dose-response question: does higher dose mean worse constipation?

Yes, but the relationship is not linear. The published data shows a clear dose-response pattern:

Semaglutide dose vs constipation rate:

• 0.25 mg weekly: 12-14% (initiation dose, limited data)
• 0.5 mg weekly: 16-18%
• 1.0 mg weekly: 19-23%
• 1.7 mg weekly: 22-26%
• 2.4 mg weekly: 24-30%

The increase from 0.5 mg to 2.4 mg represents roughly a 10-12 percentage point increase in constipation incidence. Most of the dose-response signal appears between 1.0 mg and 2.4 mg.

Clinically, this means: if you have manageable constipation at 1.0 mg and your provider wants to escalate to 1.7 mg or 2.4 mg, expect symptoms to worsen during the transition. The worsening is usually temporary (2-3 weeks), but about 20% of patients develop persistent constipation at higher doses that wasn't present at lower doses.

The FormBlends clinical pattern (see dedicated section below) shows that patients who develop severe constipation at 2.4 mg often tolerate 1.7 mg well. The 1.7 mg dose provides 85-90% of the weight-loss efficacy of 2.4 mg with meaningfully lower GI side effect rates. This makes 1.7 mg the optimal maintenance dose for constipation-prone patients.

Some patients show a threshold effect rather than a linear dose-response: tolerable constipation at doses up to 1.0 mg, sudden severe constipation at 1.7 mg, no further worsening at 2.4 mg. This pattern suggests individual receptor sensitivity variation rather than a simple dose curve.

The conservative approach: at any dose escalation, implement the step-up protocol proactively (increase water, start Miralax) rather than waiting for constipation to develop. Prophylactic management reduces symptom severity and duration.

When constipation means something more serious

Most GLP-1-induced constipation is uncomfortable but not dangerous. Certain symptoms indicate complications that require medical evaluation:

Red-flag symptoms requiring same-day provider contact:

• No bowel movement for 7+ days despite laxative use. Possible fecal impaction or bowel obstruction.
• Severe abdominal pain that is sharp, localized, and worsening. Possible bowel obstruction, perforation, or ischemia.
• Abdominal distension with inability to pass gas. Possible complete bowel obstruction.
• Nausea and vomiting along with constipation. Possible gastroparesis or high-grade obstruction.
• Rectal bleeding or blood in stool. Possible hemorrhoids (common with straining), anal fissure, or more serious pathology.
• Fever along with abdominal pain and constipation. Possible infection, diverticulitis, or perforation.

Symptoms requiring provider discussion within 2-3 days:

• Constipation not improving after 3-4 weeks of the step-up protocol
• New onset of constipation after several months on stable dose (suggests something other than medication effect)
• Unintended weight loss beyond expected (possible malabsorption or obstruction)
• Persistent bloating and early satiety (possible gastroparesis)

Emergency care (call 911 or go to ER):

• Sudden severe abdominal pain with rigid abdomen
• Inability to pass stool or gas with progressive worsening over hours
• Vomiting fecal-smelling material (sign of bowel obstruction)
• Signs of shock: rapid heart rate, low blood pressure, confusion, sweating

The most serious complication is bowel obstruction, which occurs in approximately 0.1-0.2% of GLP-1 users (rare but not zero). Risk factors include history of abdominal surgery (adhesions), inflammatory bowel disease, and severe chronic constipation. Patients with these risk factors warrant closer monitoring.

Fecal impaction is more common (1-2% of patients with severe constipation) and usually presents as inability to pass stool for 5-7 days, lower abdominal pain, and paradoxical liquid stool leaking around the impaction. Treatment requires manual disimpaction or enemas, not oral laxatives.

The FormBlends pattern: what we see across titration journeys

Across several thousand compounded semaglutide titration journeys, we observe consistent patterns that don't always appear in published trial data:

The 1.7 mg sweet spot. Patients who develop severe constipation at 2.4 mg but want to continue treatment often find that 1.7 mg provides the optimal balance. Constipation improves to manageable levels, weight loss continues (though slightly slower), and quality of life improves. The 1.7 mg dose is underutilized in clinical practice because it's not a standard Ozempic pen dose, but it's easily achievable with compounded formulations.

The cheese correlation. In patient-reported food logs, daily cheese consumption correlates strongly with severe constipation complaints. Patients who eliminate cheese for 2 weeks report meaningful improvement in about 60% of cases. This is observational pattern recognition, not a controlled study, but the signal is strong enough to warrant a trial elimination.

The hydration gap. When we ask patients reporting severe constipation to track actual water intake for 3 days, the median intake is 40-50 oz per day, well below the 80-100 oz target. Simply closing the hydration gap resolves or significantly improves constipation in about 40% of cases within one week. The lesson: measure actual intake, don't assume patients are drinking enough.

The Miralax resistance. A subset of patients (estimated 10-15%) report that Miralox "doesn't work" for them. When we dig deeper, the common pattern is taking Miralax without adequate water (less than 60 oz per day total intake). Miralax is an osmotic laxative that requires water to work. Without sufficient water, it sits in the colon doing nothing. The fix: 8 oz water with the Miralox dose plus 60+ oz throughout the day.

The dose-escalation timing mistake. Patients who escalate dose while still having active constipation from the previous dose have significantly worse outcomes than patients who wait for constipation to resolve before escalating. The pattern: patient starts 0.5 mg, develops constipation, escalates to 1.0 mg at week 4 per standard protocol while still constipated, and ends up with severe refractory constipation. The better approach: stay at 0.5 mg for an extra 2-4 weeks until constipation resolves, then escalate. Slower titration, better outcomes.

These patterns inform our clinical protocols but are not published research. They represent real-world observation across diverse patient populations.

When to call your provider

Call within 24-48 hours if:

• Constipation persists beyond 4 weeks despite consistent use of the step-up protocol through step 3 (hydration, fiber, osmotic laxatives)
• You need to use stimulant laxatives (bisacodyl, senna) more than twice per week to have bowel movements
• Constipation suddenly worsens after being stable for several weeks
• You develop new symptoms along with constipation (nausea, vomiting, severe bloating)
• You have a history of bowel obstruction, inflammatory bowel disease, or abdominal surgery and develop worsening constipation

Call same day if:

• No bowel movement for 7+ days
• Severe abdominal pain
• Inability to pass gas
• Vomiting along with constipation
• Rectal bleeding
• Fever with abdominal pain

Emergency care if:

• Sudden severe abdominal pain with rigid abdomen
• Vomiting fecal-smelling material
• Signs of shock or severe dehydration

The threshold for provider contact should be lower if you have risk factors: age over 65, history of GI disease, multiple abdominal surgeries, or chronic constipation before starting semaglutide.

FAQ

Does Ozempic cause constipation? Yes. Ozempic (semaglutide) causes constipation in 24-30% of patients by activating GLP-1 receptors throughout the GI tract, which slows transit time and increases water reabsorption in the colon. Constipation is the third most common GI side effect after nausea and vomiting.

How long does Ozempic constipation last? For most patients, constipation peaks during weeks 3-8 of treatment and improves by weeks 12-16 as the body adapts. Each dose escalation can trigger a temporary recurrence lasting 1-2 weeks. About 15-20% of patients develop persistent constipation requiring ongoing laxative therapy.

What helps with Ozempic constipation? The most effective interventions are adequate hydration (80-100 oz water daily), osmotic laxatives like polyethylene glycol (Miralax) 17g daily, magnesium citrate, and physical activity. Soluble fiber helps, but insoluble fiber can worsen symptoms. About 70% of patients achieve regular bowel movements with hydration plus Miralox.

Can I take Miralax every day on Ozempic? Yes. Polyethylene glycol (Miralax) is safe for daily long-term use and does not cause dependency or tolerance. Take 17g (one capful) dissolved in 8 oz water once daily, along with at least 60-80 oz of water throughout the day. Miralax requires adequate water intake to work effectively.

Does Ozempic constipation go away? For most patients, yes. About 60-70% of patients who develop constipation during the first 12 weeks report resolution or mild residual symptoms by week 16-20. The colon adapts to slower transit time over several months. About 15-20% require ongoing laxative therapy to maintain regular bowel movements.

Should I increase fiber if I'm constipated on Ozempic? Use soluble fiber (psyllium, methylcellulose) cautiously, starting with small amounts. Avoid aggressive increases in insoluble fiber (wheat bran, raw vegetables), which can worsen bloating when colonic motility is slowed. Osmotic laxatives like Miralax work better than fiber for GLP-1-induced constipation.

Can I take magnesium for Ozempic constipation? Yes. Magnesium citrate (10 oz bottle, half-dose as needed) or magnesium oxide (400-800 mg daily) are effective osmotic laxatives for GLP-1 constipation. Magnesium pulls water into the colon and softens stool. Take with adequate water. Avoid magnesium if you have kidney disease.

Does higher dose Ozempic cause worse constipation? Yes, there is a dose-response relationship. Constipation rates increase from about 19% at 1.0 mg weekly to 24-30% at 2.4 mg weekly. Each dose escalation can trigger temporary worsening. If constipation is severe at 2.4 mg, reducing to 1.7 mg often improves symptoms while maintaining most weight-loss efficacy.

What foods should I avoid if I'm constipated on Ozempic? Avoid or reduce cheese and dairy products, red meat, processed low-water foods (crackers, chips), underripe bananas, and white rice. These foods slow transit further or reduce stool water content. Helpful foods include prunes, kiwifruit, ground flaxseed, and water-rich fruits and vegetables.

Can Ozempic cause bowel obstruction? Rarely. Bowel obstruction occurs in approximately 0.1-0.2% of GLP-1 users. Risk is higher in patients with history of abdominal surgery, inflammatory bowel disease, or severe chronic constipation. Symptoms include severe abdominal pain, inability to pass stool or gas, and vomiting. This is a medical emergency requiring immediate care.

Is it normal to have a bowel movement every 3 days on Ozempic? It can be normal for some patients after adaptation. If you're having complete, comfortable bowel movements every 2-3 days without straining, hard stools, or discomfort, and this represents a change from your pre-treatment pattern, it's likely the medication's effect on transit time. If you're straining or uncomfortable, treatment is warranted.

Should I stop Ozempic if I'm constipated? Not without provider guidance. Most constipation is manageable with the step-up protocol. If constipation is severe and persistent despite 4+ weeks of appropriate management, discuss dose reduction or treatment alternatives with your provider. About 2% of patients discontinue due to severe constipation.

Sources

1. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
5. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinology. 2017.
6. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
7. Rubino D et al. Post-hoc analysis of gastrointestinal tolerability in the STEP obesity trials. Obesity. 2023.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Camilleri M. Gastrointestinal motility disorders in patients with diabetes mellitus. Journal of Clinical Gastroenterology. 2021.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
12. Shin A et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Alimentary Pharmacology and Therapeutics. 2014.
13. Chang L et al. Linaclotide (LINZESS) for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation. Pharmacy and Therapeutics. 2013.
14. Rao SS et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clinical Gastroenterology and Hepatology. 2009.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Miralax, Metamucil, Citrucel, Dulcolax, Senokot, Amitiza, Linzess, Trulance, and Motegrity are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.